# Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

> **NCT03565991** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 202 (actual)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors
- Genes, BRCA 1

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT03565991
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-18
- **Primary completion:** 2022-03-28
- **Final completion:** 2023-02-03
- **Target enrollment:** 202 (ACTUAL)
- **Why stopped:** The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522)
- **Last updated:** 2023-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03565991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03565991, "Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03565991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*